Third Ordinary General Meeting of Shareholders of Basilea Pharmaceutica AG

 

In his presentation to shareholders today, Anthony Man MD, Basilea's CEO, reflected on the 2003 business year as follows:

 

 "We achieved our ambitious goals in 2003 that formed a solid foundation for the successful IPO that occurred in March this year.  We can look forward with confidence to 2004 and to advancing our development compounds further along the value chain as fast as possible."

 

 

Approval of the annual report, annual financial statements and consolidated financial statements 2003 of the Group.

Release of the members of the Board of Directors and of the Management.

Carry forward of the accumulated loss.

Re-election of Werner Henrich, Peter Friedli and Dr. Andreas Wicki as Board members for a term of three years.

Election of Dr. Anthony Man (CEO) and Ronald Scott (CFO) as Board members for a term of one year.

Re-election of PricewaterhouseCoopers AG, Basel, as Auditors and Auditors of the consolidated financial statements of the Group for the financial year 2004.

 

The Ordinary General Meeting of Shareholders 2004 of Basilea Pharmaceutica AG was attended by shareholders, who represented 5,028,757 votes, i.e. 68.14% of the total share capital of the Company.

 

 

Basilea Pharmaceutica AG (BSLN) is an independent biopharmaceutical company headquartered in Basel, Switzerland that is actively engaged in the discovery and development of innovative medicines for the treatment of unmet medical needs. 

 

The company's fully integrated research and development operations are currently focused on new anti-bacterial, anti-fungal and dermatology drugs.  Basilea was founded in October 2000 with significant resources to discover, develop and bring innovative medicines to market.  Basilea is listed on the SWX (Swiss Exchange).

 

This communication expressly or implicitly contains certain forward-looking statements concerning Basilea Pharmaceutica AG and its business.  Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.  Basilea Pharmaceutica AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.  For further information, please contact the following: